Pharmafile Logo
Pharmafocus logo
Advanced Search

Bayer

Showing 15 posts of 262 posts found.

Bayer’s cardiovascular drug races to target in trial

February 9, 2017
Research and Development, Sales and Marketing Bayer, Janssen, Xarelto

Bayer has been putting its blood-thinning drug, Xarelto, through its paces in a Phase 3 trial to determine whether it …

News
money-256281_960_720

Five most talked about mergers and acquisitions of 2016

January 27, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actavis, Bayer, Boehringer, Johnson & Johnson, Sanofi, Teva, acquisition, mergers, monsanto, pharma

2017 has kicked off with a bang – as Johnson & Johnson confirmed a $30 billion deal to takeover of …

Feature

Looking back at the biggest deal of 2016: Bayer-Monsanto

December 2, 2016
Medical Communications Bayer, acquisition, big deal, monsanto, pharma deal 2016

The industry followed Bayer’s attempts to acquire US agricultural firm Monsanto with fevered anticipation; the takeover eventually closed in September …

News
germany-flag-flying-german-breeze-flag-pole-waving-1398668

Roche, Bayer and more speak out against German pricing cap plans

November 14, 2016
Sales and Marketing Bayer, Germany, Roche

A number of major drug manufacturers have spoken out against German government plans to cap prescription drug pricing in the …

News
regeneron

Regeneron and Ocular Therapeutix to collaborate in potential $315 million deal

October 14, 2016
Medical Communications Bayer, Eyelea, Ocular Therapeutix, Regeneron Pharmaceuticals, wet AMD

Regeneron Pharmaceuticals and Ocular Therapeutix have entered into a deal that will see them collaborate to develop a sustained release …

News
finance

Sanofi lowers Q3 sales figures from 2015

October 13, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Cipro, Plavix, Sanofi, financial results

Sanofi lowered its aggregate sales figure for Q3 2016 from €9.59 billion to €9.46 billion ahead of the release of …

News
janssen_stairs_1

Johnson & Johnson failed to inform FDA over faulty blood testing device in Phase III trial

September 29, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Johnson & Johnson, Xarelto, phase III, warfarin

The British Medical Journal, after its own investigation, found that Janssen knew early into the Phase III trial, known as …

News
eylea-product-box-md

NICE approves Bayer’s Eylea for NHS use

September 28, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Eylea, NICE

Bayer has announced that its Eylea (aflibercept) drug has received a final recommendation from NICE for the treatment of visual …

News

Bayer CEO defends $66 billion Monsanto acquisition

September 20, 2016
Manufacturing and Production, Sales and Marketing Bayer, Werner Baumann, monsanto

Bayer AG’s chief executive Werner Baumann has spoken in defence of the company’s move last week to acquire US agricultural …

News
4420456374_64a3d7e6aa

Top Ten articles in the Pharma Industry this week

September 16, 2016
Medical Communications Bayer, GSK, Gilead, GlaxoSmithKline, J&J, JJ, Pfizer, Roche, Sanofi, Takeda, aspen, google, monsanto

As we come to the end of another week, we’re looking back at an exciting week in the industry; there …

News

Bayer acquires Monsanto in largest-ever deal by a German company

September 14, 2016
Business Services, Manufacturing and Production, Sales and Marketing Bayer, acqusition, monsanto

Bayer and Monsanto have signed a definitive merger agreement under which the German drugmaker will acquire the US agricultural group …

News

Bayer ponders $1.1 billion portfolio sale to fund Monsanto acquisition

September 12, 2016
Business Services, Manufacturing and Production, Sales and Marketing Bayer, acquisition, monsanto

In the latest development in the Bayer-Monsanto saga, the German drugmaker has enlisted the aid of global financial services firm …

News

Bayer takes another shot at Monsanto acquisition

September 6, 2016
Manufacturing and Production, Sales and Marketing Bayer, acqusition, monsanto

Bayer has made another move to acquire US-based Monsanto, raising the price it is prepared to pay in an effort …

News

NICE recommends Bayer’s Xofigo for prostate cancer treatment

September 2, 2016
Medical Communications, Sales and Marketing Bayer, NICE, approval, prostate cancer, recommendation, xofigo

NICE has issued final draft guidance recommending Bayer’s Xofigo (radium-223 dichloride) for the treatment of prostate cancer. Previously, the drug …

News
eylea-product-box-md

NICE recommends Eylea as first-line treatment for sight threatening condition

August 24, 2016
Research and Development, Sales and Marketing Bayer, Eylea, NHS, NICE, first-line treatment

Bayer has announced that the National Institute for Health and Care Excellence (NICE) has recommended Eylea (aflibercept) as a cost-effective …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025